mercaptopurine
mercaptopurine: 25 clinical trials tracked.
mercaptopurine evidence translation
What we can confirm
25 tracked trials
What it means
What to watch
Prepared research question
What is verified about mercaptopurine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 7 study sponsors
Related indications
Clinical Trials (25)showing 10 most recent
A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)
Primary endpoint: Dose limiting toxicities (Safety run-in: Cohort A)
A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)
Modified LCH-III Regimen Versus Modified LCH-III Regimen Combined With Luvometinib in the Treatment of Multisystem Pediatric Langerhans Cell Histiocytosis: A Multicenter, Open-Label, Randomized Controlled Clinical Trial
Primary endpoint: Event-Free survival rate
A Phase 2 Study Evaluating the Safety and Efficacy of Asparaginase Erwinia Chrysanthemi- Recombinant-Rywn (Recombinant Erwinia Asparaginase) During Pediatric-Inspired Regimen in High-Risk Adults With Newly Diagnosed ALL or LBL
Primary endpoint: Incidence of adverse events (AEs) (Safety Lead-in)
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
Primary endpoint: Incidence of dose-limiting toxicities (DLTs) (safety phase)
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia
Primary endpoint: Philadelphia chromosome-positive (Ph+) (BCR::ABL1-rearranged) 3-year event free survival (EFS)
SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Primary endpoint: End of induction minimal residual disease negative remission
SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Primary endpoint: Minimal residual disease (MRD)-negativity rate in patients with T cell acute lymphoblastic leukemia
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Primary endpoint: Minimal Residual Disease
A Randomized Phase II Study Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Plus Blinatumomab Compared to Usual Chemotherapy Plus Blinatumomab for Older Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Primary endpoint: Event-free survival